1 Rare damaging *CCR*² variants are associated with lower lifetime cardiovascular risk

2

Marios K. Georgakis, MD, PhD*¹⁻³, Rainer Malik, PhD*¹, Omar El Bounkari, PhD¹, Natalie R. 3 Hasbani, MPH⁴, Jiang Li MD, PhD⁵, Jennifer E. Huffman, PhD⁶, Gabrielle Shakt^{7,8}, Reinier W. P. 4 Tack, MD^{2,9}, Tamara N. Kimball, MD^{2,10}, Yaw Asare, PhD¹, Alanna C. Morrison, PhD⁴, BS, Noah 5 L. Tsao, BS^{7,8}, Renae Judy, MS^{7,8}, Braxton D. Mitchell, PhD^{11,12}, Huichun Xu, MD, PhD¹¹, May 6 E. Montasser, PhD¹¹, Ron Do, PhD^{13,14}, Eimear E. Kenny^{13,15-17}, Ruth J.F. Loos, PhD¹³, James 7 G. Terry, MS¹⁸, John Jeffrey Carr, MD¹⁸, Joshua C. Bis, PhD¹⁹, Bruce M. Psaty, MD, PhD¹⁹⁻²¹. 8 W. T. Longstreth, MD, MPH^{21,22}, Kendra A Young, MSPH, PhD²³, Sharon M Lutz, PhD^{24,25}, 9 Michael H Cho, MD, MPH²⁶, Jai Broome, BA²⁷, Alyna T. Khan²⁷, Fei Fei Wang, BS²⁷, Nancy 10 Heard-Costa, PhD^{28,29}, Sudha Seshadri, MD³⁰, Ramachandran S. Vasan, MD^{28,29,31}, Nicholette 11 D. Palmer, PhD³², Barry I. Freedman, MD³³, Donald W. Bowden, PhD³², Lisa R. Yanek, MPH³⁴, 12 13 Brian G. Kral, MD, MPH³⁴, Lewis C. Becker, MD³⁴, Patricia A. Peyser, PhD³⁵, Lawrence F. Bielak, DDS, MPH³⁵, Farah Ammous, PhD³⁵, April P. Carson, PhD, MSPH³⁶, Michael E. Hall, 14 MD, MS³⁶, Laura M. Raffield, PhD³⁷, Stephen S. Rich, PhD³⁸, Wendy S. Post, MD³⁹, Russel P. 15 Tracy, PhD⁴⁰, Kent D. Taylor, PhD⁴¹, Xiuqing Guo, PhD⁴¹, Michael C. Mahaney, PhD⁴², Joanne 16 E. Curran, PhD⁴², John Blangero, PhD⁴², Shoa L. Clarke, MD, PhD⁴³⁻⁴⁵, Jeffrey W. Haessler, 17 MS⁴⁶, Yao Hu, PhD⁴⁶, Themistocles L. Assimes, MS, PhD⁴³⁻⁴⁵, Charles Kooperberg, PhD⁴⁶, 18 Jürgen Bernhagen, PhD^{1,3,51}, Christopher D. Anderson, MD, MMSc^{2,9,10}, Scott M. Damrauer, 19 MD^{7,8,47}, Ramin Zand MD, MPH^{48,49}, Jerome I. Rotter, MD⁴¹, Paul S. de Vries, PhD⁴, Martin 20 Dichgans, MD^{1,3,50,51} 21

22

¹ Institute for Stroke and Dementia Research (ISD), University Hospital, Ludwig-Maximilians-

24 University (LMU), Munich, Germany

²⁵ ² Program in Medical and Population Genetics, Broad Institute of MIT and Harvard, Cambridge,

- 26 MA, USA
- ³ Munich Cluster for Systems Neurology (SyNergy), Munich, Germany.
- ⁴ Human Genetics Center, Department of Epidemiology, Human Genetics, and Environmental
- Sciences, School of Public Health, The University of Texas Health Science Center at Houston,
 Houston, TX, USA
- ⁵ Department of Molecular and Functional Genomics, Geisinger Health System, Danville,
- 32 Pennsylvania, USA
- 33 ⁶ Veterans Affairs Healthcare System, Boston, MA, USA
- ⁷ Department of Surgery, Perelman School of Medicine at the University of Pennsylvania,
- 35 Philadelphia, PA, USA

- 36 ⁸ Corporal Michael Crescenz VA Medical Center, Philadelphia, PA, USA
- ⁹Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA, USA
- ¹⁰ Department of Neurology, Brigham and Women's Hospital, Boston, MA, USA
- 39 ¹¹ Department of Medicine, University of Maryland School of Medicine, Baltimore, MD
- 40 ¹² Geriatrics Research and Education Clinical Center, Baltimore Veterans Administration
- 41 Medical Center, Baltimore, MD
- 42 ¹³ The Charles Bronfman Institute for Personalized Medicine, Icahn School of Medicine at Mount
- 43 Sinai, New York, NY, USA
- ¹⁴ Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai,
 New York, NY, USA
- 46 ¹⁵ The Center for Genomic Health, Icahn School of Medicine at Mount Sinai, New York, NY,
- 47 USA
- 48 ¹⁶ Pamela Sklar Division of Psychiatric Genomics, Icahn School of Medicine at Mount Sinai,
- 49 New York, NY, USA
- 50 ¹⁷ Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA
- ¹⁸ Department of Radiology, Vanderbilt University Medical Center, Nashville, TN, USA
- 52 ¹⁹ Cardiovascular Health Research Unit, Department of Medicine, University of Washington,
- 53 Seattle, WA, USA
- ²⁰ Department of Health Systems and Population Health, University of Washington, Seattle, WA,
- 55 USA
- 56 ²¹ Department of Epidemiology, University of Washington, Seattle, WA, USA
- 57 ²² Department of Neurology, University of Washington, Seattle, WA, USA
- ²³ Department of Epidemiology, University of Colorado Anschutz Medical Campus, Aurora CO,
 USA
- 60 ²⁴ Department of Population Medicine, PRecisiOn Medicine Translational Research
- 61 (PROMoTeR) Center, Harvard Pilgrim Health Care and Harvard Medical School, Boston, MA,
- 62 USA
- 63 ²⁵ Department of Biostatistics, T.H. Chan School of Public Health, Harvard University, Boston,
- 64 MA, USA
- ²⁶ Channing Division of Network Medicine, Brigham and Women's Hospital, Harvard Medical
- 66 School, Boston, MA, USA
- 67 ²⁷ Department of Biostatistics, University of Washington, Seattle, WA, USA
- 68 ²⁸ Department of Medicine, Boston University School of Medicine, Boston, MA, USA
- ²⁹ Boston University and National Heart, Lung, and Blood Institute's Framingham Heart Study,
- 70 Framingham, MA, USA

- ³⁰ Bigg's Institute for Alzheimer's Disease and neurodegenerative disorders, University of Texas
- 72 Health Science Center, San Antonio, TX, USA
- ³¹ Department of Epidemiology, Boston University School of Public Health, Boston, MA, USA
- 74 ³² Department of Biochemistry, Wake Forest School of Medicine, Winston-Salem, NC, USA
- ³³ Section on Nephrology, Department of Internal Medicine, Wake Forest School of Medicine,
- 76 Winston-Salem, NC, USA
- ³⁴ Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA
- ³⁵ Department of Epidemiology, School of Public Health, University of Michigan, Ann Arbor, MI,
- 79 USA
- 80 ³⁶ Department of Medicine, University of Mississippi Medical Center, Jackson, MS
- 81 ³⁷ Department of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, NC
- 82 ³⁸ Center for Public Health Genomics, University of Virginia, Charlottesville, VA USA
- ³⁹ Johns Hopkins Bloomberg School of Public Health, Johns Hopkins School of Medicine,
- 84 Baltimore, MD USA
- ⁴⁰ Departments of Pathology & Laboratory Medicine, and Biochemistry, Larner College of
 Medicine, University of Vermont, Burlington, VT USA
- ⁴¹ The Institute for Translational Genomics and Population Sciences, Department of Pediatrics,
- 88 The Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Torrance,
- 89 CA USA
- 90 ⁴² Department of Human Genetics and South Texas Diabetes and Obesity Institute, University of
- 91 Texas Rio Grande Valley School of Medicine, Brownsville TX USA
- 92 ⁴³ Department of Medicine (Division of Cardiovascular Medicine), Stanford University School of
- 93 Medicine, Stanford, CA, USA
- 94 ⁴⁴ Stanford Cardiovascular Institute, Stanford, CA, USA
- 95 ⁴⁵ VA Palo Alto Health Care System, Palo Alto, CA, USA
- 96 ⁴⁶ Division of Public Health Sciences, Fred Hutchinson Cancer Center, Seattle WA 98109 USA
- 97 ⁴⁷ Department of Genetics, Perelman School of Medicine at the University of Pennsylvania,
- 98 Philadelphia, PA, USA
- ⁴⁸ Department of Neurology, Pennsylvania State University, Hershey, Pennsylvania, USA.
- ⁴⁹ Department of Neurology, Neuroscience Institute, Geisinger Health System, Danville, PA,
- 101 USA
- ⁵⁰ German Centre for Neurodegenerative Diseases (DZNE), Munich, Germany
- ⁵¹ German Centre for Cardiovascular Research (DZHK, Munich), partner site Munich Heart
- 104 Alliance, Munich, Germany
- 105

106 *equally contributed

107

- 108
- 109

110 Address for Correspondence:

Marios K. Georgakis, MD, PhD	Martin Dichgans, MD					
Clinician-Scientist	Director					
E-mail: marios.georgakis@med.uni-muenchen.de;	E-mail: martin.dichgans@med.uni-					
mgeorgak@broadinstitute.org	<u>muenchen.de</u>					
Tel: +49-89-4400-46156	Tel: +49-89-4400-46019					
Institute for Stroke and Dementia Research, Ludwig-Maximilians-University Hospital						
Feodor-Lynen-Str. 17, 81377 Munich, Germany						

111

113 ABSTRACT

114

Background: Previous work has shown a role of CCL2, a key chemokine governing monocyte trafficking, in atherosclerosis. However, it remains unknown whether targeting CCR2, the cognate receptor of CCL2, provides protection against human atherosclerotic cardiovascular disease.

119 Methods: Computationally predicted damaging or loss-of-function (REVEL>0.5) variants within 120 CCR2 were detected in whole-exome-sequencing data from 454,775 UK Biobank participants 121 and tested for association with cardiovascular endpoints in gene-burden tests. Given the key 122 role of CCR2 in monocyte mobilization, variants associated with lower monocyte count were 123 prioritized for experimental validation. The response to CCL2 of human cells transfected with 124 these variants was tested in migration and cAMP assays. Validated damaging variants were 125 tested for association with cardiovascular endpoints, atherosclerosis burden, and vascular risk 126 factors. Significant associations were replicated in six independent datasets (n=1,062,595).

127 Results: Carriers of 45 predicted damaging or loss-of-function CCR2 variants (n=787 128 individuals) were at lower risk of myocardial infarction and coronary artery disease. One of 129 these variants (M249K, n=585, 0.15% of European ancestry individuals) was associated with 130 lower monocyte count and with both decreased downstream signaling and chemoattraction in 131 response to CCL2. While M249K showed no association with conventional vascular risk factors, 132 it was consistently associated with a lower risk of myocardial infarction (Odds Ratio [OR]: 0.66 95% Confidence Interval [CI]: 0.54-0.81, p=6.1x10⁵) and coronary artery disease (OR: 0.74 133 95%CI: 0.63-0.87, p=2.9x10⁻⁴) in the UK Biobank and in six replication cohorts. In a phenome-134 135 wide association study, there was no evidence of a higher risk of infections among M249K 136 carriers.

137 Conclusions: Carriers of an experimentally confirmed damaging *CCR2* variant are at a lower 138 lifetime risk of myocardial infarction and coronary artery disease without carrying a higher risk of 139 infections. Our findings provide genetic support for the translational potential of CCR2-targeting 140 as an atheroprotective approach.

141

142 Key words: atherosclerosis, CCR2, genetics, inflammation, cardiovascular disease

143

144 INTRODUCTION

Atherosclerotic cardiovascular disease (CVD) is the leading cause of morbidity and mortality 145 worldwide.¹⁻³ Over 20 years of preclinical research have provided overwhelming evidence for a 146 causal role of inflammation in atherogenesis^{4,5} and recent trials provided proof-of-concept that 147 targeting inflammation can lead to reductions in adverse cardiovascular events.⁶⁻⁸ The 148 149 canakinumab anti-inflammatory thrombosis outcome study (CANTOS) demonstrated that 150 treatment with a monoclonal antibody against IL-1ß lowers risk of recurrent vascular events among individuals with recent myocardial infarction.⁶ The colchicine cardiovascular outcomes 151 trial (COLCOT)⁷ and the low-dose colchicine-2 (LoDoCo2) trial⁸ further showed that colchicine, 152 an established drug with widespread inhibitory effects on inflammatory pathways,^{9,10} lowers the 153 154 risk of recurrent vascular events in patients with coronary artery disease (CAD). Targeting 155 inflammation for atheroprotection must be balanced against the impact on any host defense 156 responses. For example, both canakinumab⁶ and colchicine⁷ were associated with adverse 157 effects including fatal infections in the CANTOS and the colchicine trials. While translational efforts have mostly focused on the inflammasome-IL-1β/IL-6 axis,¹¹ evidence from preclinical 158 159 studies and early-phase clinical trials highlights the promise of alternative cytokines⁵ for the development of a second generation of atherosclerosis-centered anti-inflammatory treatments.⁴ 160

161 CC-motif chemokine ligand 2 (CCL2) is a pivotal inflammatory chemokine regulating monocyte trafficking¹² that has been studied as a potential target in atherosclerosis. Preclinical data 162 163 suggest that pharmacological targeting of CCL2 or its receptor CCR2 might lower atherosclerosis burden in experimental models.¹³ However, only recently large-scale genetic 164 165 and epidemiological studies have highlighted the relevance of the CCL2/CCR2 pathway in human CVD, calling for clinical translation of strategies targeting this pathway.¹⁴ Prospective 166 observational studies^{15,16} support associations of higher circulating CCL2 levels with ischemic 167 168 stroke and cardiovascular death, whereas Mendelian randomization analyses from population genetic studies^{17,18} show associations with higher risk of ischemic stroke and coronary artery 169 170 disease. Furthermore, CCL2 levels are higher in atherosclerotic lesions from patients with 171 symptomatic carotid stenosis, as compared to asymptomatic disease and are associated with features of plaque vulnerability.¹⁹ 172

Although these studies support a role of the CCL2/CCR2 axis in human atherosclerosis, it remains unclear whether pharmacological intervention in this pathway could lead to atheroprotection in humans. Several molecules targeting CCR2 are currently under development for autoimmune disease, liver disease, and cancer and could be repurposed for prevention of atherosclerotic cardiovascular disease.¹⁴ Studies examining the phenotypic effects

of rare genetic variants in population-based studies have been instrumental in predicting the consequences of pharmacological interventions²⁰⁻²⁴ and might thus serve as a validation step for drug targets under development.

181 Here, we leveraged whole-exome sequencing (WES) data from 454,775 participants of the 182 population-based UK Biobank (UKB) study to explore whether rare damaging variants in the 183 CCR2 gene are associated with cardiovascular disease risk, burden of atherosclerosis, and 184 traditional vascular risk biomarkers. We experimentally confirmed the damaging effects of one 185 variant (M249K), which has a frequency of 0.15% among UKB participants of European 186 ancestry and replicated its effects on cardiovascular risk in external population- and hospital-187 based biobanks. Finally, we performed a phenome-wide association study across two biobanks 188 to explore associations of this damaging variant with the risk of infections or other potential 189 safety signals of any CCR2-targeting treatments.

190

191 METHODS

192 Study population

We used data from the UKB, a population-based prospective cohort study of UK residents aged 193 40-69 years recruited between 2006-2010 from 22 assessment centers across the UK.²⁵ This 194 195 analysis was restricted to 454,775 out of 502,419 participants with available whole-exome 196 sequencing data (UKB Exome 450k release from October 2021). Primary and secondary 197 analyses were performed with an updated Functional Equivalence (FE) protocol that retains 198 original quality scores in the CRAM files (referred to as the OQFE protocol). We included only variants that met published criteria²⁶; individual and variant missingness <10%. Hardy Weinberg 199 200 Equilibrium p-value>10⁻¹⁵, minimum read coverage depth of 7 for SNPs and 10 for indels, at 201 least one sample per site passed the allele balance threshold >0.15 for SNPs and 0.20 for 202 indels. We used genotype array data released by the UKB study to assign individuals to 203 continental ancestry super-groups (African (AFR), Hispanic or Latin American (HLA, originally 204 referred to as 'AMR' by the 1000 Genomes Project), East Asian (EAS), European (EUR) and 205 South Asian (SAS)) by projecting each sample onto reference principal components (PCs) 206 calculated from the 1000 Genomes reference panel. We included only individuals without 207 evidence of relatedness within the UKB samples, as defined by a KING cut-off of <0.084.

208

209 Detection of damaging genetic variants in CCR2 and experimental validation

Restricting our analyses to the *CCR2* gene, we detected predicted LoF or damaging missense variants with a MAF<1% in the *CCR2* exonic region and then explored which of those are associated with monocyte count as a functional readout. Variants from WES were annotated as previously described²⁷ using VEP v101.^{28,29} We used the LofTee plugin for predicting LoF variants³⁰ and a REVEL cutoff of >0.5 from dbNSFP version 4.0a for predicted damaging missense mutations.

216 We aimed to further restrict our analyses to damaging variants with proven functional effects. 217 One of the key functions of the CCL2 axis is the recruitment of classical monocytes from the bone marrow to the circulation in a CCR2-dependent way.³¹⁻³³ Consequently, damaging 218 219 variants in the CCR2 gene would be expected to be associated with a lower monocyte count in 220 the circulation. To test associations with the circulating counts of monocytes and other white 221 blood cells (WBC), absolute counts were extracted from the UKB fields 30160 (basophil counts), 222 30150 (eosinophil counts), 30130 (monocyte counts), 30120 (lymphocyte counts) and 30140 223 (neutrophil counts). Distributions were visually checked for normal distribution and lognormalized when needed. Associations were tested using regenie v2.2.4.³⁴ For WBC analyses, 224 225 we used sex, age at blood draw, and the first 5 ancestral PCs as covariates. The mixed model 226 parameters were estimated using 200,000 genotyped common variants. Saddle point 227 approximation regression was applied. Genetic variants associated with monocyte count at a 228 false discovery rate (FDR)-corrected p-value <0.05 were prioritized for further experimental 229 validation. To test whether the associations are specific for monocyte count, we also tested 230 associations with other WBC counts (basophils, eosinophils, lymphocytes, neutrophils) for each 231 variant.

232 Two predicted damaging CCR2 variants showing a significant association with lower monocyte 233 count were brought forward to experimental testing. The two variants were M249K 234 (3:46358273:T:A) and W165S (3:46358021:G:C, both hq38). First, we tested how human 235 CCR2-knockout monocytic THP-1 cells transfected with these variants or wild-type CCR2 236 respond to chemoattraction by CCL2 using a Transwell migration assay (details in 237 Supplementary Methods). Next, we tested whether M249K-mutant CCR2 (which showed an 238 effect in the migration assay) influences cAMP production in response to CCL2 in transfected 239 human HEK293T cells (details in Supplementary Methods).

240

241 Associations with cardiovascular risk, atherosclerosis burden and vascular risk factors

242 Focusing on two sets of variants, we then explored associations of CCR2 variants with clinical 243 cardiovascular endpoints including myocardial infarction, coronary artery disease, acute 244 ischemic stroke, peripheral artery disease, and abdominal aortic aneurysm using ICD-10- and 245 ICD-9- coded diagnoses, OPCS4-coded procedures, self-report, and algorithmically-defined 246 phenotypes provided by the UKB as detailed in **Supplementary Table S1**. As our hypothesis 247 was that these variants would lead to reductions in risk by lowering the lifetime burden of 248 atherosclerosis, we also constructed a combined phenotype of atherosclerosis manifestations in 249 four vascular beds (coronary arteries, cerebrovascular system, peripheral arteries of the 250 extremities, and aortic atherosclerosis). Severe atherosclerosis was defined as presence of 251 clinical manifestations in at least two vascular beds (Supplementary Table S1).

252 We followed two approaches to test associations with these phenotypes: (i) we performed a 253 burden test combining all predicted damaging variants (LoF or REVEL >0.5) within CCR2: (ii) 254 focusing on M249K, the only damaging monocyte-lowering CCR2 variant that was 255 experimentally validated in the migration and cAMP assays, we performed logistic regression 256 analysis adjusted for age, sex, and the first 5 ancestral PCs testing. We included both prevalent 257 and incident endpoints as outcomes in all analyses and used Firth's correction for unbalanced 258 case/control ratios in our logistic regression analysis. To explore whether the associations with 259 cardiovascular risk are mediated through known vascular risk factors, we further tested 260 associations of the damaging genetic variants with the following phenotypes: systolic and 261 diastolic blood pressure, circulating LDL and HDL cholesterol, circulating apolipoprotein B 262 levels, circulating glycated hemoglobin A1c (HbA1c) concentration, body mass index, and C-263 reactive protein. Individuals under antihypertensive medications were excluded in the analyses 264 for systolic and diastolic blood pressure, individuals under lipid-lowering medications were 265 excluded from the analyses for LDL and HDL cholesterol and apolipoprotein B levels, and 266 individuals under glucose-lowering treatments were excluded from the analyses for HbA1c.

267

268 Validation of M249K CCR2 variant in external datasets and meta-analysis

For external validation, we obtained summary statistics from six different data sources based on a pre-defined protocol: the TransOmics and Precision Medicine Program supported by NHLBI (TOPMed) Program including multiple studies and a trans-ancestry population in the US (n=51,732), the population-based deCODE dataset in Iceland (n=345,992), the hospital-based Penn Medicine Biobank (PMBB, n=43,721), the Million Veteran Programme (MVP, n=438,905), the Geisinger DiscovEHR-MyCode cohort in central and northeastern Pennsylvania (n=145,826), as well as the hospital-based Mass General Brigham Biobank (MGBB, n=36,419).

276 Specifically, we requested data from logistic regression models adjusted for age, sex, race, 277 study-specific variables (e.g. sequencing center) and the first 10 PCs (with the Firth's correction) 278 for the M249K variant. The variant was either assessed by sequencing or directly genotyped in 279 all cohorts. Details about the individual cohorts are provided in **Supplementary Methods**. The 280 derived odds ratios (OR) from the six datasets were meta-analyzed using fixed-effects and 281 random-effects meta-analyses and were subsequently also meta-analyzed with the results from 282 the UKB. We set a significance threshold of p<0.05 in the replication meta-analysis. Heterogeneity was assessed with the I² and the Cochran Q statistic. 283

284

285 Phenome-wide association study

286 To explore potential adverse effects associated with damaging CCR2 genetic variants, we 287 tested associations of M249K with the full range of clinical phenotypes encoded in the UKB and 288 replicated in an external cohort (Geisinger DiscovEHR-MyCode). We used the Phecode Map 1.2 to map UKB ICD10-codes to Phecodes³⁵ using all ICD10 codes (main position, secondary 289 290 position, death records) from the UKB. We excluded Phecodes with <100 cases and Phecodes 291 that are male- or female-specific. Individuals were assigned a case status if >1 ICD10 code was 292 mapped to the respective Phecode. To approximate effect size in a logistic regression 293 framework, we used minor allele carrier status as an independent variable and age at baseline. 294 sex and 5 ancestry PCs as covariates. We used Firth's correction for unbalanced case/control 295 ratios in our logistic regression analysis for all results with p<0.05. The results from the two 296 cohorts were meta-analyzed using fixed- and random-effects models. Heterogeneity was 297 assessed with the I² and the Cochran Q statistic.

298

299 Ethics and data availability

300 All studies have received ethical approvals from the respective ethical authorities and 301 participants in all studies have provided written informed consent. Data from the UKB are 302 available upon submission and approval of a research proposal. The UKB has institutional 303 review board approval from the Northwest Multi-Center Research Ethics Committee 304 (Manchester, UK). We accessed the data following approval of an application by the UKB Ethics 305 and Governance Council (Application No. 36993 and 2532). Summary results from the external 306 cohorts were obtained following a common pre-defined research protocol to principal 307 investigators of the study and are presented in the figures and supplementary tables. deCODE 308 has been approved by the National Bioethics Committee of Iceland, and the study was

309 conducted in agreement with conditions issued by the Data Protection Authority of Iceland 310 (VSN 14-015). All common research protocols for the TOPMed Program have been approved 311 by the institutional review board at the University of Maryland Baltimore, whereas individual 312 participating studies have obtained ethical approval from their local ethical authorities, as 313 described previously.³⁶ The Penn Medicine BioBank is approved by the University of 314 Pennsylvania, MVP by the Veterans Affairs Central Institutional Review Board, the Geisinger 315 DiscovEHR-MyCode cohort by Geisinger Institutional Review Boards, and MGBB by the Ethics 316 Committee of Mass General Brigham.

317

318 **RESULTS**

319 Computationally predicted damaging *CCR2* variants

320 Among 428,191 unrelated (out of 454,775 with whole-exome sequencing data) UK Biobank 321 participants from the whole-exome sequencing data release, we found a total of 45 predicted 322 LoF or damaging (REVEL>0.5) variants in the exonic region of the CCR2 gene distributed 323 across 787 heterozygous carriers (frequency 0.18%, Figure 1 and Supplementary Table S2). 324 There was no homozygous carrier of any of these variants and variants were predominantly 325 prevalent in individuals of European ancestry (779 carriers, frequency 0.20%), as compared to 326 individuals of African, Hispanic or Latin American, East Asian, and South Asian ancestry (total 327 of 8 carriers, pooled frequency 0.02%). Due to the very low frequency in other ancestries, we 328 restricted our analyses to individuals of European ancestry (n=393,416), Baseline 329 characteristics of the study population are presented in **Supplementary Table S3**.

330

331 Associations of *CCR2* variants with cardiovascular endpoints in gene-burden tests

332 In a discovery analysis including all 45 computationally predicted LoF or damaging variants, we 333 next explored whether genetic variation in CCR2 is associated with atherosclerotic disease 334 using a gene-based burden test. We found nominally significant associations of the predicted 335 damaging CCR2 variants with myocardial infarction (OR: 0.60, 95%CI: 0.40-0.90, p=0.008) and 336 coronary artery disease (OR: 0.76, 95%CI: 0.59-0.99, p=0.03), as well as directionally 337 consistent associations with the odds of all other examined outcomes (ischemic stroke, 338 peripheral artery disease, abdominal aortic aneurysm, Figure 2A). Variant burden was 339 associated with lower risk of a combined atherosclerotic endpoint (OR: 0.80, 95%CI: 0.65-0.98, 340 p=0.03), as well as with severe atherosclerotic disease, defined by clinical manifestations in at least two vascular beds (OR: 0.24, 95%CI: 0.07-0.82 p=0.003; Figure 2B). We found a trend for 341

a dose-response pattern with lower frequency of clinically manifest atherosclerotic disease
across the number of vascular beds involved among carriers for these *CCR2* variants
(frequency of atherosclerosis presence among carriers vs. non-carriers: in no vascular bed
88.0% vs. 90.7%; in 1 vascular bed 10.5% vs. 9.1%; in 2 vascular beds 1.2% vs. 0.3%; in 3
vascular beds 0.3% vs 0.1%, in 4 vascular beds 0.03% vs 0%; OR from ordinal regression:
0.74, 95%CI: 0.54-0.97, p=0.01).

348

349 Functional consequences of CCR2 damaging variants

To move beyond computationally predicted functional effects, we followed a two-step approach to select *CCR2* variants with functional relevance. Since one of the key functions of CCL2 is the CCR2-dependent recruitment of classical monocytes from the bone marrow to the circulation, we first tested the association of the predicted damaging variants in *CCR2* with circulating monocyte counts. We found two variants (M249K and W165S) to be associated with lower monocyte counts FDR-corrected p<0.05, **Supplementary Table S2**) and prioritized them for experimental validation.

357 We tested whether transfection of human CCR2-knockout THP-1 monocytes with either of these 358 two variants influences directed migration towards CCL2 in a trans-migration cell assay. Cells 359 transfected with M249K showed a clearly reduced response to CCL2, when compared to cells 360 transfected with wild-type CCR2, resembling the response of CCR2-knockout cells (Figure 3A 361 and Supplementary Figure S1). Cells transfected with W165S showed a profile similar to cells 362 transfected with wild-type CCR2 (Supplementary Figure S1). HEK293T cells transfected with 363 M249K further showed a profound reduction of cAMP production in response to CCL2, when 364 compared to HEK293T cells transfected with wild-type CCR2 (Figure 3B).

M249K has a frequency of 0.15% among UKB participants of European ancestry and leads to the replacement of methionine by lysine in the sixth transmembrane domain of the CCR2 receptor (**Figure 1**). Confirming the specificity of the consequences of M249K on monocyte recruitment, we found no evidence of associations with any of the other leukocyte type counts in the UKB (**Figure 3C**).

370

371 Associations of M249K with cardiovascular risk and replication in external cohorts

Carriers of the M249K variant were at lower risk of myocardial infarction (OR: 0.62 95%CI: 0.40-0.97, p=0.03) and coronary artery disease (OR: 0.73 95%CI: 0.56-0.97, p=0.02) in the UKB (**Figure 4A**). As expected, given that M249K was by far the most frequent among

375 computationally predicted damaging CCR2 variants, we found associations with a lower risk of 376 the combined atherosclerosis endpoint, as well as significantly lower risk of severe 377 atherosclerosis (manifestations in ≥ 2 vascular beds, **Figure 4B**), similar to the burden test. To 378 explore whether the effects of M249K are mediated through effects on risk factors targeted by 379 current preventive approaches, we next tested associations with established biomarkers of 380 vascular risk. We found no associations with any of the tested vascular risk factors including 381 blood pressure, hyperglycemia, or circulating lipids. Furthermore, there was no evidence of 382 association with the levels of the known inflammatory biomarker C-reactive protein, thus 383 suggesting that the effects might be independent of factors targeted by current atheroprotective 384 anti-inflammatory treatments (Figure 4C).

385 As these associations were only nominally significant and suggestive of an effect of this variant, 386 we aimed to externally replicate our findings to provide robust evidence for an association with a 387 lower risk of myocardial infarction and coronary artery disease. To externally replicate the 388 effects of M249K, we meta-analyzed data from six external datasets (TOPMed, deCODE, 389 PMBB, MGB, MVP, Geisinger). The frequency of the variant varied between the six datasets 390 (range: 0.0006% in MVP to 0.228% in Geisinger), totaling 767 heterozygous carriers among 391 1,062,595 individuals (91,420 myocardial infarction and 142,361 coronary artery disease 392 cases). When meta-analyzing data from the six cohorts for the association between carrying 393 M249K and risk of myocardial infarction or coronary artery disease, the ORs were comparable 394 to those of the UKB (OR for myocardial infarction: 0.67 95%CI: 0.53-0.85, p=0.0006; OR for 395 coronary artery disease: 0.74 95%CI: 0.53-0.85, p=0.003, Supplementary Figure S2 and 396 **Supplementary Table S4**). When meta-analyzing these data with UKB reaching a sample size 397 of 1,456,011 individuals including 1,314 M249K carriers (111,394 and 207,019 cases of 398 myocardial infarction and coronary artery disease, respectively), we found M249K carriers to 399 have 34% lower odds of suffering a myocardial infarction (OR: 0.66 95%CI: 0.54-0.81, 400 $p=6.1 \times 10^{-5}$) and 26% lower odds of coronary artery disease (OR: 0.74 95%CI: 0.63-0.87, p=2.9x10⁻⁴, Figure 4D-E, Supplementary Table S4). 401

402

403 Phenome-wide association study

As a last step, we performed a PheWAS to explore whether M249K is associated with potential
adverse effects that would raise signals for possible side-effects of any CCR2-targeting
treatments. Because we lacked statistical power for most of the outcomes, we restricted our
analyses to endpoints with ≥10 cases in the carrier group of the UKB. To increase statistical
power, we meta-analyzed our results with the Geisinger cohort. Across all phenotypes only

409 myocardial infarction showed an association with M249K that passed the FDR-corrected p<0.05 410 threshold. Coronary atherosclerosis and angina pectoris were also less frequent (p<0.05) 411 among carriers although only at a nominal non-corrected p<0.05 (**Figure 4A**). No infectious 412 disease phenotypes were found to be more common (p<0.05) among M249K carriers 413 (**Supplementary Table S5**). Senile cataract was more common among carriers (p<0.05). 414 Among UKB participants, we found no evidence for an association between carrier status for a 415 *CCR2* damaging variants and survival over a 15-year follow-up period (**Figure 4B**).

416

417 **DISCUSSION**

418 Using data from 1.5M individuals we found that heterozygous carriers of a rare experimentally 419 confirmed damaging CCR2 variant (M249K) are at lower lifetime risk of myocardial infarction 420 and coronary artery disease. Carriers of this variant showed no differences in LDL cholesterol, 421 blood pressure, BMI, HbA1c and C-reactive protein levels, indicating that damaging CCR2 422 variants exert their effects independently of conventional vascular risk factors targeted by 423 available atheroprotective treatments. On the other hand, we found no evidence of associations 424 with higher risk of infectious diseases or overall mortality among carriers. Collectively, our 425 results provide genetic support for CCR2 as a potential therapeutic target for atherosclerotic 426 cardiovascular disease.

427 Our findings extend our previous results from a Mendelian randomization study suggesting a 428 higher atherosclerosis risk among individuals with genetic predisposition to elevated CCL2 429 levels.¹⁷ That study focused on common genetic variants distributed across the genome and 430 shown to influence CCL2 levels in trans. In contrast, the current study assessed damaging rare 431 genetic variants within the CCR2 gene. The functional impact of M249K, the most frequent 432 variant among those associated with atherosclerotic disease, was experimentally confirmed. As 433 such, our results are unlikely to be confounded by pleiotropic effects of the variants. Despite the 434 lack of data from clinical trials targeting CCR2 in patients with cardiovascular disease, studies in 435 experimental models of atherosclerosis have provided supportive evidence for an atheroprotective effect of pharmacologically targeting CCR2.¹³ 436

437 Our work consistently connects these findings to humans and provides a rationale for 438 conducting a clinical trial with pharmacological targeting of CCR2 in patients with 439 atherosclerosis. Ultimately, only clinical testing can provide evidence in favor of or against 440 pharmacological targeting of CCR2 for patients with atherosclerosis. A major bottleneck for 441 initiating a clinical trial would be the need for proof of concept in a phase 2 trial before a trial with

hard endpoint is conducted. Given the evidence that CRP levels are not directly affected by the 442 CCL2/CCR2 axis,¹⁵ an intermediate endpoint is needed that captures plague inflammation, and 443 in particular, macrophage accumulation.¹³ PET imaging, particularly with an FDG tracer, has 444 445 shown promise for detecting macrophage content in large plaques and has already been used in phase 2 trials targeting plaque inflammation.³⁷⁻³⁹ In addition, recent advances in tracer 446 447 development have enabled the development of a tracer that specifically binds to CCR2.⁴⁰ Initial 448 data from patients have shown promise in imaging monocyte recruitment to the heart following mvocardial infarction.⁴⁰ 449

450 Interestingly, we found no evidence supporting a connection of M249K with established 451 pharmacological targets of atherosclerosis, such as LDL cholesterol, hyperglycemia, or elevated 452 blood pressure. This implies that any benefit from CCR2-targeting approaches would be 453 expected to be independent of available preventive approaches against atherosclerotic disease. 454 Also, we found no evidence of associations with circulating C-reactive protein levels, a 455 biomarker of the activity of the IL-6 signaling pathway that is also the target of atheroprotective anti-inflammatory treatments currently under development.⁴¹ Based on this, our findings suggest 456 457 that CCR2 inhibition might have an atheroprotective effect on top of such approaches, which in 458 turn might be an argument to pursue approaches embracing combination therapies.

459 Our PheWAS analysis was limited by low statistical power. Nevertheless, it is noteworthy that 460 we found no evidence for an association of M249K with risk of infections, which is a potential 461 barrier to the use of atheroprotective anti-inflammatory treatments. This is in line with previous 462 early phase clinical trials testing inhibitors of CCR2 for other indications, which also found no important safety concerns.⁴²⁻⁴⁴ Furthermore, we found no evidence of associations with overall 463 464 survival, minimizing concerns about a significant impact on unknown fatal adverse effects. The 465 reason why we do not see a protective effect on survival despite the effect on risk of myocardial 466 infarction could be related to statistical power and length of follow-up. It is a common 467 observation that medications with strong effects on lowering cardiovascular risk, such as statins, 468 have failed to show survival benefits.

469 Our study has limitations. First, despite leveraging the largest available whole-exome 470 sequencing studies totaling almost 1.5 million individuals, our results for the PheWAS analyses 471 are still limited by low statistical power and should be interpreted cautiously. Given the rarity of 472 the damaging *CCR2* variants, any association with rare potential side-effects would ultimately 473 be undetectable in the context of this study. While formal statistical replication is precluded by 474 this power issue, the consistent effect directions and the overall significance of the meta-475 analysis raise confidence that the identified association is valid. Further, our main results for

476 associations between M249K and myocardial infarction or coronary artery disease failed to 477 reach the formal thresholds of statistical significance for gene-based or variant-based testing $(2.7 \times 10^{-6} \text{ and } 5 \times 10^{-8}, \text{ respectively})$. As such, this result should be interpreted as suggestive. 478 479 Genetic analyses with rare variants are still underpowered, as also highlighted in recent burden 480 test studies from the UK Biobank, where no gene showed significant associations with either 481 myocardial infarction or ischemic stroke.⁴⁵ Future research should aim to pool additional data as 482 they become available. Second, UK Biobank consists primarily of European individuals, and 483 consequently, we detected damaging CCR2 variants that are predominantly detected in 484 European populations. As such, our results should not be extended to non-European 485 individuals. Third, all analyses are based on individuals heterozygous for the damaging CCR2 486 variants, as we found no homozygotes for damaging CCR2 variants. While this lack of 487 homozygotes can be fully explained by the frequency of damaging CCR2 variants in the general 488 population, it remains unknown whether homozygous status for damaging CCR2 variants would 489 lead to potentially fatal complications. Fourth, the data from the UKB do not allow a distinction to 490 be made between classical and non-classical monocytes. The available data suggest that CCL2 only acts on classical CCR2+ monocytes in humans or Ly6C^{hi} monocytes in mice. Experimental 491 studies in mice have revealed that Ccr2-deficient Lv6C^{hi} monocytes are trapped in the bone 492 marrow and are not mobilized after infections.³¹ Future studies in humans should further explore 493 494 the impact of the examined mutations on monocytes subtypes. However, it should be noted that 495 inhibition of monocyte recruitment from the circulation into atherosclerotic lesions is the main 496 suspected mechanism by which CCR2 damaging variants act, and the effects of lowering 497 monocyte counts remain to be tested.

In conclusion, we found that heterozygous carriers of a rare damaging *CCR*² variant are at lower lifetime risk of myocardial infarction and coronary artery disease without carrying a higher risk of infections. This provides further genetic support for the concept that pharmacological targeting of CCR2 might be an efficient and viable immunotherapeutic strategy to prevent atherosclerotic cardiovascular disease.

503

504 **Conflicts of Interest:** SMD receives research support from RenalytixAI and personal fees from 505 Calico Labs, both outside the current work. MEM receives funding from Regeneron 506 Pharmaceutical Inc. unrelated to this work. RD has received research support from AstraZeneca 507 and Goldfinch Bio, not related to this work. BMP serves on the Steering Committee of the Yale 508 Open Data Access Program funded by Johnson & Johnson. CDA has received sponsored 509 research support from Bayer AG, has consulted for ApoPharma, and is a member of the

Editorial Board of *Neurology*. LMR is a consultant for the TOPMed Administrative Coordinating
Center (through WeStat). The other authors have nothing to declare.

512

513 Acknowledgements: Marios K. Georgakis is supported with a clinician-scientist grant from the 514 Munich Cluster for Systems Neurology (EXC 2145 SyNergy, ID 390857198), and an Emmy 515 Noether grant (GZ: GE 3461/2-1, ID 512461526) by the German Research Foundation 516 (Deutsche Forschungsgemeinschaft, DFG), as well as by the Fritz-Thyssen Foundation (Ref. 10.22.2.024MN) and the Hertie Foundation (Hertie Network of Excellence in Clinical 517 518 Neuroscience, ID P1230035). Scott M. Damrauer is supported by IK2-CX001780. We 519 acknowledge the Penn Medicine BioBank (PMBB) for providing data and thank the patient-520 participants of Penn Medicine who consented to participate in this research program. We would 521 also like to thank the Penn Medicine BioBank team and Regeneron Genetics Center for providing genetic variant data for analysis. The PMBB is approved under IRB protocol# 813913 522 523 and supported by Perelman School of Medicine at University of Pennsylvania, a gift from the 524 Smilow family, and the National Center for Advancing Translational Sciences of the National 525 Institutes of Health under CTSA award number UL1TR001878. We thank Geisinger MyCode 526 Community Health Initiative and Geisinger-Regeneron DiscovEHR collaboration contributors 527 who have been critical in the generation of the original data used for this study. This publication 528 does not represent the views of the Department of Veterans Affairs or the United States 529 Government. Paul S. de Vries, Natalie R. Hasbani, and Alanna C. Morrison were supported by R01 HL146860. Joshua C. Bis and Bruce M. Psaty were funded in part by R01HL105756. 530 531 Reading of the carotid IMT measures was supported by N01HC85085, N01HC45133; Coronary 532 Calcium scans were supported by R01HL64587. Kendra A. Young is supported by NHLBIn U01 533 HL089897 and U01 HL089856. Sharon M. Lutz was supported by R01 MH129337. Nicholette 534 D. Palmer, Barry I. Freedman and Donald W. Bowden were supported by R01 AG058921. 535 Patricia A. Peyser was supported by R01 HL146860. Lawence F. Bielak was supported by R01 536 HL146860. LMR was supported by T32 HL129982 and by the National Center for Advancing 537 Translational Sciences, National Institutes of Health, through Grant KL2TR002490. Christopher 538 D. Anderson receives sponsored research support from the US National Institutes of Health 539 (R01NS103924, U01NS069673), the American Heart Association (AHA 21SFRN812095). 540 Whole genome sequencing (WGS) for the Trans-Omics in Precision Medicine (TOPMed) 541 program was supported by the National Heart, Lung and Blood Institute (NHLBI). Cohort-542 specific acknowledgements for studies included in the TOPMed program are provided in 543 Supplementary Table S6. Jürgen Bernhagen is supported by grants from the Deutsche

Forschungsgemeinschaft (DFG; CRC 1123 [A3], BE 1977/14-1, and Munich Cluster for
Systems Neurology [SyNergy, EXC 2145; ID390857198]. Martin Dichgans is supported by
grants from the Deutsche Forschungsgemeinschaft (DFG; CRC 1123 [B3], DI-722/16-1 [ID:
428668490], DI-722/21-1, and Munich Cluster for Systems Neurology [SyNergy, EXC 2145;
ID390857198]), the Leducq Foundation, the flagship P4-medicine project *DigiMe*d Bayern and
the Vascular Dementia Research Foundation.

550

551

553 **REFERENCES**

- Diseases GBD, Injuries C. Global burden of 369 diseases and injuries in 204 countries
 and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study
 2019. Lancet. 2020;396:1204-1222. doi: 10.1016/S0140-6736(20)30925-9
- Guedeney P, Claessen BE, Kalkman DN, Aquino M, Sorrentino S, Giustino G, Farhan S,
 Vogel B, Sartori S, Montalescot G, et al. Residual Inflammatory Risk in Patients With
 Low LDL Cholesterol Levels Undergoing Percutaneous Coronary Intervention. *J Am Coll Cardiol.* 2019;73:2401-2409. doi: 10.1016/j.jacc.2019.01.077
- 562 3. Ridker PM. How Common Is Residual Inflammatory Risk? *Circ Res.* 2017;120:617-619.
 563 doi: 10.1161/CIRCRESAHA.116.310527
- 5644.Lutgens E, Atzler D, Doring Y, Duchene J, Steffens S, Weber C. Immunotherapy for565cardiovascular disease. *Eur Heart J.* 2019;40:3937-3946. doi: 10.1093/eurheartj/ehz283
- 566 5. Weber C, Noels H. Atherosclerosis: current pathogenesis and therapeutic options. *Nat*567 *Med.* 2011;17:1410-1422. doi: 10.1038/nm.2538
- 568 Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C, Fonseca 6. 569 F, Nicolau J, Koenig W, Anker SD, et al. Antiinflammatory Therapy with Canakinumab 570 for Atherosclerotic Disease. Ν Engl J Med. 2017;377:1119-1131. doi: 571 10.1056/NEJMoa1707914
- Tardif JC, Kouz S, Waters DD, Bertrand OF, Diaz R, Maggioni AP, Pinto FJ, Ibrahim R,
 Gamra H, Kiwan GS, et al. Efficacy and Safety of Low-Dose Colchicine after Myocardial
 Infarction. *The New England journal of medicine*. 2019;381:2497-2505. doi:
 10.1056/NEJMoa1912388
- Nidorf SM, Fiolet ATL, Mosterd A, Eikelboom JW, Schut A, Opstal TSJ, The SHK, Xu
 XF, Ireland MA, Lenderink T, et al. Colchicine in Patients with Chronic Coronary
 Disease. *N Engl J Med*. 2020;383:1838-1847. doi: 10.1056/NEJMoa2021372
- 579 9. Leung YY, Yao Hui LL, Kraus VB. Colchicine--Update on mechanisms of action and
 580 therapeutic uses. Semin Arthritis Rheum. 2015;45:341-350. doi:
 581 10.1016/j.semarthrit.2015.06.013
- Opstal TSJ, Hoogeveen RM, Fiolet ATL, Silvis MJM, The SHK, Bax WA, de Kleijn DPV,
 Mosterd A, Stroes ESG, Cornel JH. Colchicine Attenuates Inflammation Beyond the
 Inflammasome in Chronic Coronary Artery Disease: A LoDoCo2 Proteomic Substudy.
 Circulation. 2020;142:1996-1998. doi: 10.1161/CIRCULATIONAHA.120.050560

11. Ridker PM. From C-Reactive Protein to Interleukin-6 to Interleukin-1: Moving Upstream
To Identify Novel Targets for Atheroprotection. *Circ Res.* 2016;118:145-156. doi:
10.1161/CIRCRESAHA.115.306656

- 589 12. Mackay CR. Chemokines: immunology's high impact factors. *Nat Immunol*. 2001;2:95590 101.
- 591 13. Živković L, Asare Y, Bernhagen J, Dichgans M, Georgakis MK. Pharmacological
 592 Targeting of the CCL2/CCR2 Axis for Atheroprotection: A Meta-Analysis of Preclinical
 593 Studies. *Arteriosclerosis, thrombosis, and vascular biology*. 2022;42:e131-e144. doi:
 594 10.1161/atvbaha.122.317492
- 595 14. Georgakis MK, Bernhagen J, Heitman LH, Weber C, Dichgans M. Targeting the CCL2596 CCR2 axis for atheroprotection. *Eur Heart J.* 2022;43:1799-1808. doi:
 597 10.1093/eurheartj/ehac094
- Georgakis MK, Malik R, Bjorkbacka H, Pana TA, Demissie S, Ayers C, Elhadad MA,
 Fornage M, Beiser AS, Benjamin EJ, et al. Circulating Monocyte Chemoattractant
 Protein-1 and Risk of Stroke: Meta-Analysis of Population-Based Studies Involving 17
 180 Individuals. *Circ Res.* 2019;125:773-782. doi: 10.1161/CIRCRESAHA.119.315380
- 602 16. Georgakis MK, de Lemos JA, Ayers C, Wang B, Björkbacka H, Pana TA, Thorand B,
 603 Sun C, Fani L, Malik R, et al. Association of Circulating Monocyte Chemoattractant
 604 Protein-1 Levels With Cardiovascular Mortality: A Meta-analysis of Population-Based
 605 Studies. *JAMA Cardiol.* 2021;6:587-592. doi: 10.1001/jamacardio.2020.5392
- Georgakis MK, Gill D, Rannikmae K, Traylor M, Anderson CD, Lee JM, Kamatani Y,
 Hopewell JC, Worrall BB, Bernhagen J, et al. Genetically Determined Levels of
 Circulating Cytokines and Risk of Stroke. *Circulation*. 2019;139:256-268. doi:
 10.1161/CIRCULATIONAHA.118.035905
- Georgakis MK, Parodi L, Frerich S, Mayerhofer E, Tsivgoulis G, Pirruccello JP, Slowik A,
 Rundek T, Malik R, Dichgans M, et al. Genetic Architecture of Stroke of Undetermined
 Source: Overlap with Known Stroke Etiologies and Associations with Modifiable Risk
 Factors. *Ann Neurol.* 2022;91:640-651. doi: 10.1002/ana.26332
- 614 Georgakis MK, van der Laan SW, Asare Y, Mekke JM, Haitjema S, Schoneveld AH, de 19. 615 Jager SCA, Nurmohamed NS, Kroon J, Stroes ESG, et al. Monocyte-Chemoattractant 616 Protein-1 Levels in Human Atherosclerotic Lesions Associate With Plaque Vulnerability. 617 biology. Arteriosclerosis. thrombosis. and vascular 2021;41:2038-2048. doi: 618 10.1161/atvbaha.121.316091
- 619 20. Interleukin-6 Receptor Mendelian Randomisation Analysis C, Swerdlow DI, Holmes MV,
 620 Kuchenbaecker KB, Engmann JE, Shah T, Sofat R, Guo Y, Chung C, Peasey A, et al.

The interleukin-6 receptor as a target for prevention of coronary heart disease: a
mendelian randomisation analysis. *Lancet.* 2012;379:1214-1224. doi: 10.1016/S01406736(12)60110-X

- Cohen JC, Boerwinkle E, Mosley TH, Jr., Hobbs HH. Sequence variations in PCSK9,
 low LDL, and protection against coronary heart disease. *The New England journal of medicine*. 2006;354:1264-1272. doi: 10.1056/NEJMoa054013
- Clarke R, Peden JF, Hopewell JC, Kyriakou T, Goel A, Heath SC, Parish S, Barlera S,
 Franzosi MG, Rust S, et al. Genetic variants associated with Lp(a) lipoprotein level and
 coronary disease. *N Engl J Med*. 2009;361:2518-2528. doi: 10.1056/NEJMoa0902604
- Nioi P, Sigurdsson A, Thorleifsson G, Helgason H, Agustsdottir AB, Norddahl GL,
 Helgadottir A, Magnusdottir A, Jonasdottir A, Gretarsdottir S, et al. Variant ASGR1
 Associated with a Reduced Risk of Coronary Artery Disease. *N Engl J Med.*2016;374:2131-2141. doi: 10.1056/NEJMoa1508419
- 634 24. Stitziel NO, Khera AV, Wang X, Bierhals AJ, Vourakis AC, Sperry AE, Natarajan P, 635 Klarin D, Emdin CA, Zekavat SM, et al. ANGPTL3 Deficiency and Protection Against 636 Disease. J Am Coll Cardiol. Coronary Artery 2017;69:2054-2063. doi: 637 10.1016/j.jacc.2017.02.030
- Sudlow C, Gallacher J, Allen N, Beral V, Burton P, Danesh J, Downey P, Elliott P, Green
 J, Landray M, et al. UK biobank: an open access resource for identifying the causes of a
 wide range of complex diseases of middle and old age. *PLoS Med.* 2015;12:e1001779.
 doi: 10.1371/journal.pmed.1001779
- Backman JD, Li AH, Marcketta A, Sun D, Mbatchou J, Kessler MD, Benner C, Liu D,
 Locke AE, Balasubramanian S, et al. Exome sequencing and analysis of 454,787 UK
 Biobank participants. *Nature*. 2021;599:628-634. doi: 10.1038/s41586-021-04103-z
- Malik R, Beaufort N, Frerich S, Gesierich B, Georgakis MK, Rannikmäe K, Ferguson AC,
 Haffner C, Traylor M, Ehrmann M, et al. Whole-exome sequencing reveals a role of
 HTRA1 and EGFL8 in brain white matter hyperintensities. *Brain : a journal of neurology.*2021;144:2670-2682. doi: 10.1093/brain/awab253
- McLaren W, Gil L, Hunt SE, Riat HS, Ritchie GR, Thormann A, Flicek P, Cunningham F.
 The Ensembl Variant Effect Predictor. *Genome Biol.* 2016;17:122. doi: 10.1186/s13059016-0974-4
- loannidis NM, Rothstein JH, Pejaver V, Middha S, McDonnell SK, Baheti S, Musolf A, Li
 Q, Holzinger E, Karyadi D, et al. REVEL: An Ensemble Method for Predicting the
 Pathogenicity of Rare Missense Variants. *Am J Hum Genet.* 2016;99:877-885. doi:
 10.1016/j.ajhg.2016.08.016

- Karczewski KJ, Francioli LC, Tiao G, Cummings BB, Alfoldi J, Wang Q, Collins RL,
 Laricchia KM, Ganna A, Birnbaum DP, et al. The mutational constraint spectrum
 quantified from variation in 141,456 humans. *Nature*. 2020;581:434-443. doi:
 10.1038/s41586-020-2308-7
- Serbina NV, Pamer EG. Monocyte emigration from bone marrow during bacterial
 infection requires signals mediated by chemokine receptor CCR2. *Nat Immunol.*2006;7:311-317. doi: 10.1038/ni1309
- 32. Tsou CL, Peters W, Si Y, Slaymaker S, Aslanian AM, Weisberg SP, Mack M, Charo IF.
 Critical roles for CCR2 and MCP-3 in monocyte mobilization from bone marrow and
 recruitment to inflammatory sites. *J Clin Invest.* 2007;117:902-909. doi:
 10.1172/JCI29919
- Shi C, Jia T, Mendez-Ferrer S, Hohl TM, Serbina NV, Lipuma L, Leiner I, Li MO,
 Frenette PS, Pamer EG. Bone marrow mesenchymal stem and progenitor cells induce
 monocyte emigration in response to circulating toll-like receptor ligands. *Immunity*.
 2011;34:590-601. doi: 10.1016/j.immuni.2011.02.016
- Mbatchou J, Barnard L, Backman J, Marcketta A, Kosmicki JA, Ziyatdinov A, Benner C,
 O'Dushlaine C, Barber M, Boutkov B, et al. Computationally efficient whole-genome
 regression for quantitative and binary traits. *Nat Genet*. 2021;53:1097-1103. doi:
 10.1038/s41588-021-00870-7
- Wu P, Gifford A, Meng X, Li X, Campbell H, Varley T, Zhao J, Carroll R, Bastarache L,
 Denny JC, et al. Mapping ICD-10 and ICD-10-CM Codes to Phecodes: Workflow
 Development and Initial Evaluation. *JMIR Med Inform*. 2019;7:e14325. doi:
 10.2196/14325
- Taliun D, Harris DN, Kessler MD, Carlson J, Szpiech ZA, Torres R, Taliun SAG, Corvelo
 A, Gogarten SM, Kang HM, et al. Sequencing of 53,831 diverse genomes from the
 NHLBI TOPMed Program. *Nature*. 2021;590:290-299. doi: 10.1038/s41586-021-03205-y
- Fayad ZA, Mani V, Woodward M, Kallend D, Abt M, Burgess T, Fuster V, Ballantyne
 CM, Stein EA, Tardif JC, et al. Safety and efficacy of dalcetrapib on atherosclerotic
 disease using novel non-invasive multimodality imaging (dal-PLAQUE): a randomised
 clinical trial. *Lancet*. 2011;378:1547-1559. doi: 10.1016/s0140-6736(11)61383-4
- Gaztanaga J, Farkouh M, Rudd JH, Brotz TM, Rosenbaum D, Mani V, Kerwin TC, Taub
 R, Tardif JC, Tawakol A, et al. A phase 2 randomized, double-blind, placebo-controlled
 study of the effect of VIA-2291, a 5-lipoxygenase inhibitor, on vascular inflammation in
 patients after an acute coronary syndrome. *Atherosclerosis*. 2015;240:53-60. doi:
 10.1016/j.atherosclerosis.2015.02.027

- 39. van Wijk DF, Sjouke B, Figueroa A, Emami H, van der Valk FM, MacNabb MH, Hemphill
 LC, Schulte DM, Koopman MG, Lobatto ME, et al. Nonpharmacological lipoprotein
 apheresis reduces arterial inflammation in familial hypercholesterolemia. *J Am Coll Cardiol.* 2014;64:1418-1426. doi: 10.1016/j.jacc.2014.01.088
- Liu Y, Imanishi T, Ikejima H, Tsujioka H, Ozaki Y, Kuroi A, Okochi K, Ishibashi K,
 Tanimoto T, Ino Y, et al. Association between circulating monocyte subsets and in-stent
 restenosis after coronary stent implantation in patients with ST-elevation myocardial
 infarction. *Circ J.* 2010;74:2585-2591. doi: 10.1253/circj.cj-10-0544
- Ridker PM, Devalaraja M, Baeres FMM, Engelmann MDM, Hovingh GK, Ivkovic M, Lo L,
 Kling D, Pergola P, Raj D, et al. IL-6 inhibition with ziltivekimab in patients at high
 atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2
 trial. *Lancet.* 2021;397:2060-2069. doi: 10.1016/S0140-6736(21)00520-1
- Friedman SL, Ratziu V, Harrison SA, Abdelmalek MF, Aithal GP, Caballeria J, Francque
 S, Farrell G, Kowdley KV, Craxi A, et al. A randomized, placebo-controlled trial of
 cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis. *Hepatology*.
 2018;67:1754-1767. doi: 10.1002/hep.29477
- de Zeeuw D, Bekker P, Henkel E, Hasslacher C, Gouni-Berthold I, Mehling H, Potarca
 A, Tesar V, Heerspink HJ, Schall TJ, et al. The effect of CCR2 inhibitor CCX140-B on
 residual albuminuria in patients with type 2 diabetes and nephropathy: a randomised
 trial. *Lancet Diabetes Endocrinol.* 2015;3:687-696. doi: 10.1016/S2213-8587(15)00261-2
- Vergunst CE, Gerlag DM, Lopatinskaya L, Klareskog L, Smith MD, van den Bosch F,
 Dinant HJ, Lee Y, Wyant T, Jacobson EW, et al. Modulation of CCR2 in rheumatoid
 arthritis: a double-blind, randomized, placebo-controlled clinical trial. *Arthritis Rheum.*2008;58:1931-1939. doi: 10.1002/art.23591
- Karczewski KJ, Solomonson M, Chao KR, Goodrich JK, Tiao G, Lu W, Riley-Gillis BM,
 Tsai EA, Kim HI, Zheng X, et al. Systematic single-variant and gene-based association
 testing of thousands of phenotypes in 394,841 UK Biobank exomes. *Cell Genom.*2022;2:100168. doi: 10.1016/j.xgen.2022.100168
- 719

720

- 721 Figure 1. Damaging CCR2 variants. Domain structure of the CCR2 protein and position of the
- 722 predicted loss-of-function (LoF) or missense damaging (REVEL>0.5) variants present in >2 UK
- 723 Biobank participants in the *CCR*2 exonic regions.
- 724





Figure 2. Associations of rare computationally predicted damaging *CCR2* variants with risk of atherosclerotic cardiovascular disease in the UK Biobank. Associations of 45 predicted loss-of-function (LoF) or damaging (REVEL>0.5) *CCR2* variants (minimum allele frequency <0.01) in burden tests with (**A**) risk of cardiovascular disease endpoints and (**B**) a combined atherosclerosis endpoint as well as severe clinical atherosclerotic disease defined by manifestations in at least 2 vascular beds (coronary arteries, cerebrovascular system, peripheral arteries of extremities, aorta) among UK Biobank participants of European ancestry. (**C**) Prevalence of clinically manifest atherosclerosis across 4 vascular beds (coronary arteries, cerebrovascular system, peripheral arteries of extremities, aorta) among CCR2 variants. The odds ratio (OR) is derived from ordinal regression adjusted for age, sex, and the first 5 ancestral principal components.



medRxiv preprint doi: https://doi.org/10.1101/2023.08.14.23294063; this version posted June 26, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.

Figure 3. Validation of the damaging effect of M249K (3:46358273:T:A) on CCL2-driven monocyte chemotaxis. (A) Experimental outline of chemotaxis assay. Transfected CCR2–/– THP-1 cells (marked in green) and non-transfected cells (marked in red) were used in a Transwell chemotaxis assay. The cells that moved to the lower chamber were collected, stained, and quantified using flow cytometry. (**B**) Chemotaxis in response to increasing concentrations of CCL2 for human *CCR2*-knockout monocytic THP-1 cells transfected with the mutant M249K vs. wild-type CCR2, as determined in a trans-well migration assay (comparisons derived from two-way ANOVA, ns: p>0.05, *** p<0.001, ****p<0.0001). (**C**) Results of cyclic AMP (cAMP) assay. Shown is the cAMP activity in HEK293T cells transfected with either empty vector or wild-type or M249K *CCR2* in response to different concentrations of CCL2. Results are presented as "Ratio 665/620 x 10,000" (ratio of fluorescence at 665 nm and 620 nm x 10,000). (**D**) Associations of M249K with counts of different leukocyte populations in the subset of European ancestry participants of the UK Biobank (N=393,838), as derived from linear regression models adjusted for age, sex, and the first 5 ancestral principal components.





Figure 4. Association of the damaging M249K CCR2 variant with lifetime cardiovascular

risk. Associations of the M249K *CCR2* variant with risk of **(A)** cardiovascular disease endpoints, **(B)** a combined atherosclerosis endpoint and severe clinical atherosclerotic disease defined by manifestations in at least 2 vascular beds (coronary arteries, cerebrovascular system, peripheral arteries of extremities, aorta), and **(C)** conventional vascular risk biomarkers in models adjusted for age, sex, and the first five principal components among UK Biobank participants of European ancestry. HbA1c and C-reactive protein levels are log-transformed for normalization. Fixed-effects and random-effects meta-analysis of the effects of M249K on risk of **(D)** myocardial infarction and **(E)** coronary artery disease across 7 population- and hospital-based biobanks. The effects correspond to odds ratios (OR) derived from logistic regression models adjusted for age, sex, and the first 5 ancestral principal components in each biobank.



Study **Cases Controls Odds Ratio** OR 95%-CI UKB 19,974 373,442 0.62 [0.40; 0.97] TOPMed 6,425 45,307 0.46 [0.22; 0.97] deCODE 25,448 320,544 0.73 [0.17; 3.19] PMBB 5,653 38,068 1.09 [0.47; 2.50] MGB 5,575 30,844 0.45 [0.20; 1.02] **MVP** 39,613 399,292 0.94 [0.61; 1.45] Geisinger 0.56 [0.39; 0.81] 8,706 137,120 Fixed effect model 111,394 1,344,617 0.66 [0.54; 0.81] Random effects model 0.66 [0.52; 0.84] Heterogeneity: $I^2 = 10\%$, p = 0.35Г 2 0.2 0.5 1 5

Е

D

Study	Cases	Controls		Odds R	atio		OR	95%-CI
UKB TOPMed deCODE PMBB MGB MVP Geisinger	46,042 12,467 43,684 9,765 14,368 53,371 27,322	392,652 48,300 306,935 33,956 22,051 266,264 118,507			 		0.41 0.50 1.73 0.41 0.95	[0.55; 0.99] [0.22; 0.78] [0.13; 1.89] [0.72; 4.16] [0.18; 0.95] [0.64; 1.40] [0.55; 0.95]
Fixed effect model Random effects mod Heterogeneity: $I^2 = 44\%$	lel	1,118,665	0.2	0.5 1	2	5		[0.63; 0.87] [0.63; 0.87]

Figure 5. Phenome-wide association study of the damaging M249K CCR2 variant and associations with overall survival. (A) Results from a phenome-wide association study in UK Biobank and the Geisinger DiscovEHR-MyCode cohort for the M249K CCR2 variant amongparticipants of European ancestry. Only phecodes with \geq 10 cases in UK Biobank were analyzed. We present the names of phenotypes associated with rare CCR2 variants at p<0.05. Only myocardial infarction reached an FDR-corrected p-value of <0.05. The results are presented as log-Odds Ratios (log-OR). (B) Kaplan-Meier curves for overall survival across 15 years of follow-up among carriers and non-carriers of the M249K CCR2 variant in the European subset of UK Biobank participants.

